rhGH in MS
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Somatropin
Growth hormone receptor agonist
What it measured
Main measures
Cumulative number of active (new or gadolinium-enhancing) lesions on brain MRI performed every four weeks during the 12-week baseline period and the first 12 weeks of the treatment period. That is, numbers of active lesions from week –8, week –4 and baseline will be compared to numbers of active lesions from week 4, week 8 and week 12.
MRI lesions
Who could take part
Relapsing MS
Inclusion: Age 18-55 years (included), female or male Exclusion: Primary progressive course of MS (PPMS)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To rule out a major increase in inflammatory disease activity by s.c. hGH using high-frequency contrast-enhanced brain MRI
Papers
Loading reviews and guidelines…
Related trials
- TOTEM-RRMS
Phase 2 · Recruiting
Still running
- Vaginal Estriol in Multiple Sclerosis
Phase 2 / Phase 3 · Completed
Met its main goal
- TOTEM-RRMS
Phase 2 · Moved to EU CTIS registry
- Estriol-MS
Phase 2 · Completed
Missed its main goal
- Safety and Tolerability of Interferon-Beta-1a and Estropr…
Phase 2 · Status unknown
Result in a paper, not read yet
- Testosterone Treatment for Multiple Sclerosis
Phase 1 / Phase 2 · Completed
Met its main goal
History
Started
May 2007
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error